TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Immune evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in physical function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Joint position sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Force sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Corticomuscular coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of the Positive and Negative Syndrome Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of vegetable consumption
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Peripheral Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical efficacy in chronic periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fit test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration of PCI-32765
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrahepatic fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Muscle health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in breast microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Received further IV fluids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SNPs identified by GWAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of sitting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary efficacy of NDV treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of NDV treatment
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day point prevalence tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate (CR/CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart pressures (PCWP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Red Blood Cell Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Participant Drop Out Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Main discharge diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Main discharge diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Main discharge diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hamilton score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FDI score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SCID diagnosis of major depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-Term Safety of Burosumab
Endpoint domain: Adverse events/effects
Primary endpoint: Long-Term Effectiveness of Burosumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Course of XLH Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reflux manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Retinal leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of RagweedMATAMPL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline average daily step count at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline average daily step count at 32 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline average daily step count at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Notch activity (expression of Hes-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Outcomes (PRO)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Response Rate (ORR) - All Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) - All Participants Treated at Recommended Phase 2 Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual muscle testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood myositis assessment scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sero-response to Hepatitis B Surface Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustainment of core program elements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in Self-Administered Psoriasis Area and Severity Index (SA-PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety: clinical relevant toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: intraoperative maximum diameter of left lobe of the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score of difficulty
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of thoracotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Febrile Neutropenia (FN)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain assessment using PIPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver variation in anovaginal distance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice severity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocal nodules size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of STRO-002
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Tolerated Dose (MTD) of STRO-002
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence of sustained arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary tumor detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Biochemical Markers of Ischemia/Reperfusion Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Biochemical Markers of Oxidative Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: auditory and vestibular function metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute psychotraumatic impact of the visit on the child
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Chronic psychotraumatic impact of the visit on the child
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological experience of the visit for the child
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of clinically significant rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor evoked potential size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of Grade 3 or Above Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperational Length of Stay in Hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean change from baseline in best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in patient-reported health status and utility using the EQ-5D-5L questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change from baseline in patient-reported low luminance visual functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in Plasma Se concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Plasma Glutathione Peroxidase 3 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Plasma Selenoprotein P concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Erythrocyte Se concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Erythrocyte Glutathione Peroxidase 1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CSF YKL40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF Tau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRSA-positivity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Faecal calprotectin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum high-sensitivity C-Reactive Protein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Preferences for CPR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of new Gd-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activities Specific Balance Confidence Scale (ABC-16)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Electrocardiogram (ECG) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participation Rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Objective response rate in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of intratumoral administration
Endpoint domain: Adverse events/effects
Primary endpoint: Excellent functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline Forced Vital Capacity (FVC) at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Forced Expiratory Volume in 1 second (FEV1) at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Peak Expiratory Flow (PEF) at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of days alive out of the hospital
Endpoint domain: Mortality/survival
Primary endpoint: proportion of subjects who do not require surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: proportion of subjects undergoing the planned versus performed type of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: disease progression based on clinical disease assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough level at 8 mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability (Frel)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vitals/ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood plasma level of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in tissue biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of pain induced by ATP vs. saline iontophoresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in blood flow induced by ATP iontophoresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: FEna
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intracerebral hemorrhage recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Ischemic stroke recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in muscle torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ability to give calories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meet nutritional goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Implantation accuracy of acetabular component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Age-Adjusted Scores in Attention Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to first catheter related infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Gall Stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants in CCS Functional Classification I and II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean number of urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Morphine Equivalent Daily Dose (MEDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients completing treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Patients Reporting Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with specific Manganese-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pregnancy Related Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in General Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Communication associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Gross Motor Function Classification System (GMFCS) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Ashworth Scale (MAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and Unexplained cry durations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Flare-Free Maintenance Until Onset of First-Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of initial investigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cost of providing the psychiatric services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: The number of Japanese participants with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed concentration (Cmax) of ALT-801
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration (AUC) vs Time Curve of ALT-801
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any ≥ Grade 3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Single Diaphragm Fiber, Specific Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Calcium Sensitivity (pCa50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphedema rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GBS Disability Score (GBS-DS) at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma Concentrations of belzutifan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about MenB vaccine efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge about potential benefits and possible side effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of tumors ablated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 6-month Progression Free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: frequency of bronchopulmonary dysplasia or death
Endpoint domain: Mortality/survival
Primary endpoint: Total quantity of alcohol consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vertical dimension at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: horizontal dimension at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soft tissue level at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate at 4 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early diagnosis of CIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Sleep Disordered Breathing (Apnea-hypopnea Index, AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Nodal metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain at 12 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence at Week 3 and Week 6 (MARS-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Persistence at Week 6
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of systemic air embolism
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of patients with monogenic diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of untreated patients starting bisphosphonate treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HIV/STI knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intestinal anastomotic leak detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of patients without progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successful completion of study measurements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Achievement of recruitment goal
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: recurrence of inguinal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage completing follow up colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Upper Extremity motor control of Fugl-Meyer Assessment (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of consent comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in perceptual and acoustic analysis of sentences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Safety and Tolerability Events
Endpoint domain: Adverse events/effects
Primary endpoint: Energy metabolism/expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with a significant cancer fingerprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: arrest in deterioration of pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: improving in pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Left Ventricular Ejection Fraction (LVEF) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes